1. Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy
- Author
-
Enrica Rumiato, Alberto Ruol, Daniela Saggioro, Sandro Malacrida, Vanna Chiarion Sileni, Alberto Amadori, Elisa Boldrin, and Giorgio Battaglia
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Esophageal Neoplasms ,medicine.medical_treatment ,Antineoplastic Agents ,Germline ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Genetics ,medicine ,Overall survival ,Humans ,PPAR delta ,Stage (cooking) ,Neoadjuvant therapy ,Aged ,Pharmacology ,Cisplatin ,Aged, 80 and over ,business.industry ,Organic Cation Transporter 1 ,Genetic Variation ,Esophageal cancer ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,business ,Pharmacogenetics ,Drug metabolism ,medicine.drug ,Follow-Up Studies - Abstract
Aim: Clinical features of esophageal cancer (EC) patients have poor prognostic power. Thus, it is paramount to discover biomarkers that can allow a more accurate survival prediction. Methods: To detect genetic variants associated with survival, DNA from 120 patients treated with cisplatin-based neoadjuvant therapy were genotyped using drug metabolism enzymes and transporters array. Results: We identified two variants: the rs2038067 in PPARD (p = 0.0004) and the rs683369 (F160L) in SLC22A1 (p = 0.001). Their prognostic power was greater than that of clinical stage alone (p = 0.017) and comparable to that of response to neoadjuvant therapy (p = 0.71). Interestingly, the prognostic accuracy of response models increased significantly when genetic variables were included (p = 0.003). Conclusion: Our data, though preliminary, strengthen the potential utility of germline variants for a better-tailored management of EC patients.
- Published
- 2020